Baidu
map

日本研究发现抗过敏药曲尼司特能改善痛经症状

2012-02-11 MedSci MedSci原创

日本一个研究小组1月16日报告说,现有的抗过敏药物曲尼司特能够有效地改善痛经症状。 许多女性受到痛经困扰,经期前后会出现腹痛、腰痛、恶心等症状,导致痛经的一个重要原因是子宫内膜异位症。 日本熊本大学研究生院教授片渊秀隆领导的研究小组从2000多种现存药物中筛选出曲尼司特,决定利用它的特性来治疗痛经。曲尼司特又名肉桂氨茴酸,是一种过敏介质阻滞剂,临床主要用于治疗支气管哮喘和过敏性鼻炎,也可用

日本一个研究小组1月16日报告说,现有的抗过敏药物曲尼司特能够有效地改善痛经症状。

许多女性受到痛经困扰,经期前后会出现腹痛、腰痛、恶心等症状,导致痛经的一个重要原因是子宫内膜异位症。

日本熊本大学研究生院教授片渊秀隆领导的研究小组从2000多种现存药物中筛选出曲尼司特,决定利用它的特性来治疗痛经。曲尼司特又名肉桂氨茴酸,是一种过敏介质阻滞剂,临床主要用于治疗支气管哮喘和过敏性鼻炎,也可用于防治过敏性皮炎及其他过敏性疾病。

曲尼司特除抗过敏外,还具有防止受伤后留下伤痕的效果,研究人员认为,伤痕的形成机制与子宫内膜异位症形成的机制有些类似,所以他们决定利用曲尼司特进行实验。

研究人员在半年时间内,让10名子宫内膜异位症患者连续服用曲尼司特,结果8人的痛经症状得到缓解,而且没有出现明显副作用。

片渊秀隆指出:“曲尼司特对子宫内膜异位症之外的原因导致的痛经应该也有效果。这会成为众多受痛经困扰的女性的福音。”不过,曲尼司特治疗痛经要想进入实用阶段还需要进行更多的临床试验

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2049567, encodeId=d332204956e8f, content=<a href='/topic/show?id=264555e961a' target=_blank style='color:#2F92EE;'>#抗过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55796, encryptionId=264555e961a, topicName=抗过敏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Sat Jan 19 10:19:00 CST 2013, time=2013-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752950, encodeId=dc2c1e529509a, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Tue Jun 26 02:19:00 CST 2012, time=2012-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294107, encodeId=1fbf129410e8a, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Feb 13 06:19:00 CST 2012, time=2012-02-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2049567, encodeId=d332204956e8f, content=<a href='/topic/show?id=264555e961a' target=_blank style='color:#2F92EE;'>#抗过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55796, encryptionId=264555e961a, topicName=抗过敏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Sat Jan 19 10:19:00 CST 2013, time=2013-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752950, encodeId=dc2c1e529509a, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Tue Jun 26 02:19:00 CST 2012, time=2012-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294107, encodeId=1fbf129410e8a, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Feb 13 06:19:00 CST 2012, time=2012-02-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2049567, encodeId=d332204956e8f, content=<a href='/topic/show?id=264555e961a' target=_blank style='color:#2F92EE;'>#抗过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55796, encryptionId=264555e961a, topicName=抗过敏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Sat Jan 19 10:19:00 CST 2013, time=2013-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752950, encodeId=dc2c1e529509a, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Tue Jun 26 02:19:00 CST 2012, time=2012-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294107, encodeId=1fbf129410e8a, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Mon Feb 13 06:19:00 CST 2012, time=2012-02-13, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map